How Can We Help You?


Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Breast Cancer Trials

Select Clinical Trial

Protocol Number: NRG-BR003

Protocol Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Eligibility: Men or women ages 18 and older, diagnosed with HER2 negative triple-negative invasive breast cancer. 

Contact Information: (910) 715-2200


Protocol Number: SWOG 1418

Protocol Title:  A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Eligibility: Women ages 18 and older, diagnosis of breast cancer with negative estrogen (ER)- and progesterone-receptor (PR) status, and negative (HER)2 receptor, with disease following therapy before surgery.

Contact Information: (910) 715-2200


Protocol Number: NRG-BR004

Protocol Title: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in first-line HER2-Positive Metastatic Breast Cancer

Eligibility: Men or women, ages 18 and older, diagnosed with HER2 positive adenocarcinoma of the breast with locally recurrent, unresectable disease or metastatic disease.

Contact Information: (910) 715-2200


Protocol Number: URCC16070, NCT 03367572

Protocol Title: Treatment of Refractory Nausea

Eligibility: Men or women ages 18 and older, receiving chemotherapy for breast cancer. 

Contact Information: (910) 715-2200


Clara McLean House
Make a Donation
News & Events